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Chronic Myeloid Leukemia (CML) develops when
unspecialized cells acquire a mutated gene known as
BCR-ABL(1). This causes the immature cell to grow
and divide uncontrollably (2). The current first line
drug used to treat CML is Imatinib. Imatinib inhibits
tyrosine kinase activity by binding to the kinase
domain of BCR-ABL (2). Although the 5-year survival
rate has increased from 6% to 90% in the last 30
years from the introduction of imatinib, there are
several mutated forms of the cancer that are
resistant to treatment(2). One such form is BCR-
ABL1(T315I) which results in a decrease in kinase
inhibition by imatinib (4). Ponatinib is one drug that is
still effective at inhibiting the kinase even in the
mutated form(4). Studies show that ponatinib potently
inhibits mutant kinase activity but causes severe
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Alkynylnicotinamide-based compounds as ABL1 (T315I) inhibitors (1)
Alyssa M. Lambrecht, Elizabeth A. Larocque, N Naganna, Clement Opoku-Temeng, 
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Docking 
Figure 4: A) Compound library of Alkynylnicotinamide- based
compounds(1) B) Enzymatic inhibition against ABL1 wild type and common
mutations T315I and E255K. Screening of compounds was done as a
service at Reaction Biology Corporation (1).
Aminoisoquinolines and Aminonaphthyridines potently inhibit ABL1 Wild type, ABL1 (T315I), and ABL1(E255K) 
Figure 1: Current first and second generation CML drugs 
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A) B)
Utilizing cell culture techniques and Prism, several
new compounds have been found to be effective
against ABL1, ABL1 (T315I) and ABL1 (E255K)
enzymes. Several compounds had competitive IC50’s
against KCL22-IR compared to ponatinib. These new
compounds allow for future research into safer
treatments for CML patients with the BCR-ABL1
(T315I) mutation.
Methods
The Sintim laboratory has developed several potent
ABL1 inhibitors, see Figure A. Cell culture was used
to determine the IC50’s shown in Table 1. The CML
cell lines K562, KCL22, and KCL22-IR were grown
in RPMI until they were confluent. Once the cells
reached confluency, they were seeded into a 96 well
plate and grown for 24 hours. Then, the cells were
treated with compounds and grown for 72 hours.
After three days, the wells were treated with
CellTiter-BlueⓇ Cell Viability Assay and incubated
for three hours. The plates were read on a plate
reader to determine the percent of living cells
compared to the DMSO control. Data was analyzed
using GraphPad Prism 7 to determine the IC50’s.
Figure 5: the presence of the alkyne allows for bypassing of
the T315I mutation (red) (1) Docking done by Elizabeth Larocque
Figure 2: Signaling Sequence of Brc-Abl
Figure 3: Experimental procedure to obtain IC50 data
Grow cells Add to 96 well plate
Treat plate (72 hrs.)
Assay cells (3hrs)
Read plate
Table 1. Calculated IC50 values of alkynyl analogues. 






































K562 KCL22R KCL22-IR 
7.01±0.07 6.45±0.13 >1μM 
25.7±1.7 35.5±1.69 >1μM 
30.05±1.9 ND ND 
10.1±0.8 111±1.35 >1μM 
161±10.8 ND ND 
43.5±1.4 ND ND 
94.5±0.8 ND ND 
25.3±0.5 17.16±0.3 >1μM 
1.85±0.03 0.18±.004 0.74±0.004 
0.587+0.004 0.606±0.606 3.27±0.09 
0.856±0.005 0.699±0.003 2.12±0.09 
0.292±0.005 1.05±0.02 1.52±0.08 
1.18±0.05 1.85±0.04 5.49±0.14 
0.833±0.005 1.48±0.05 16.3±0.7 
1.75±0.04 0.303±0.002 2.67±0.07 
0.765±0.005 1.02±0.04 4.14±0.11 
20.4±0.3 5.71±0.04 198±11.8 
6.26±0.02 1.6±0.4 ND 
0.388±0.001 0.459±0.016 3.8±0.1 
56.9±0.6 16.6±0.4 >1μM 
11.4±0.1 3.79±0.07 >1μM 
75.5±0.4 29.09±0.82 >1μM 
0.234±0.004 2.19±0.11 3.2±0.2 
1.44±0.06 1.45±0.02 13.3±0.5 
0.216±0.002 0.426±0.001 0.25±0.07 
8.44±0.05 2.25±0.03 50.1±2.23 
1.75±0.02 0.625±0.002 7.3±0.07 
0.485±0.002 0.325±0.007 4.4±0.05 
0.688±0.003 0.444±0.008 4.1±0.03 
6.59±0.01 2.59±0.04 23.3±0.6 
6.8±0.08 60.6±0.9 >1μM 
>1μM >1μM >1μM 
>1μM 731±0.09 >1μM 
0.6003±.023 0.142±.003       0.66±.005 
88.6±0.6 83.7±0.7 >1μM 
 
*IC50 values are the mean ± SD of n-3 technical replicates 
ND: not determined   
 
